X0306 4 2021-02-24 0 0001347178 Vanda Pharmaceuticals Inc. VNDA 0001785894 Jones Aranthan II C/O VANDA PHARMACEUTICALS INC. 2200 PENNSYLVANIA AVENUE, SUITE 300E WASHINGTON DC 20037 0 1 0 0 Chief Corp. Affairs Officer Common Stock 2021-02-24 4 A 0 25800 A 101287 D Common Stock 2021-02-24 4 M 0 22499 12.27 A 123786 D Common Stock 2021-02-24 4 S 0 22986 20.0136 D 100800 D Employee Stock Option (Right to Buy) 20.28 2021-02-24 4 A 0 61200 0.00 A 2031-02-23 Common Stock 61200 61200 D Employee Stock Option (Right to Buy) 12.27 2021-02-24 4 M 0 22499 0.00 D 2029-07-24 Common Stock 22499 37501 D Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. The option vested and became exercisable with respect to 25% of the shares subject to the option on July 25, 2020, and the remaining 75% of the shares vests in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the issuer through each monthly vesting date. /s/ Aranthan S. Jones II 2021-02-26